← Leaderboards
Thomas Gaj
University Of Illinois At Urbana-Champaign
$3,595,003
Attributed
$5,640,508
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,640,508 · 3
By mechanism
U01$4,091,010 · 1
R01$1,424,204 · 1
F32$125,294 · 1
Top collaborators
- Pablo Perez-Pinera6 shared
Most similar at University Of Illinois At Urbana-Champaign
Same institution · by research overlap
- Pablo Perez-Pinera$4,542,819
- Cecilia Maria Leal$4,960,916
Others in their field
Top investigators on “Mutant”
- Kc Kent Lloyd · University Of California At Davis$103,993,616
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Bruce A Beutler · Ut Southwestern Medical Center$34,438,453
- Oscar A. Carretero · Henry Ford Health System$33,594,856
- Stuart H Orkin · Children'S Hospital Boston$33,454,343
- Tracy T Batchelor · Dana-Farber Cancer Inst$31,851,614
Research focus
MutantProteinsParalysedGene TherapyAmyotrophic Lateral SclerosisProductionSuperoxide Dismutase 1NucleaseIn VivoClustered Regularly Interspaced Short Palindromic RepeatsTechnologyCellsMotor NeuronsMouse ModelGenesVariantMutationDependovirusSpinal CordGain Of Function MutationImmunologicsLinkSeveritiesDose
Grant awards (13)
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$993,968
U01 · FY2025 · NS · contact PI
Development of a CRISPR-Cas13 Gene Therapy for SOD1-Linked ALS$330,029
R01 · FY2025 · NS · contact PI
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$129,300
U01 · FY2025 · NS · contact PI
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$1,093,040
U01 · FY2024 · NS · contact PI
Development of a CRISPR-Cas13 Gene Therapy for SOD1-Linked ALS$356,539
R01 · FY2024 · NS · contact PI
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$151,047
U01 · FY2024 · NS · contact PI
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$853,800
U01 · FY2023 · NS · contact PI
Development of a CRISPR-Cas13 Gene Therapy for SOD1-Linked ALS$368,409
R01 · FY2023 · NS · contact PI
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$869,855
U01 · FY2022 · NS · contact PI
Development of a CRISPR-Cas13 Gene Therapy for SOD1-Linked ALS$369,227
R01 · FY2022 · NS · contact PI
Therapeutic genome editing for amyotrophic lateral sclerosis$13,098
F32 · FY2017 · GM · contact PI
Therapeutic genome editing for amyotrophic lateral sclerosis$58,002
F32 · FY2016 · GM · contact PI
Therapeutic genome editing for amyotrophic lateral sclerosis$54,194
F32 · FY2015 · GM · contact PI